At present, sodium-dependent glucose transporters 2 (SGLT2) inhibitor has been widely used in the treatment of T2DM and GLUT2 has also become an important target for diabetic treatment. The gene discussed is SLC2A2; the disease is type 2 diabetes mellitus.